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Abstract
Introduction: Delirium is an independent risk factor for prolonged hospital length of stay (LOS) and increased
mortality. Several antipsychotics have been studied for the treatment of intensive care unit (ICU) delirium that has
led to a high variability in prescribing patterns for these medications. We hypothesize that in clinical practice the
documentation of delirium is lower than the incidence of delirium reported in prospective clinical trials. The
objective of this study was to document the incidence of delirium diagnosed in ICU patients and to describe the
utilization of antipsychotics in the ICU.
Methods: This was a retrospective, observational, cohort study conducted at 71 United States academic medical
centers that reported data to the University Health System Consortium Clinical Database/Resource Manager. It
included all patients 18 years of age and older admitted to the hospital between 1 January 2010 and 30 June 2010
with at least one day in the ICU.
Results: Delirium was diagnosed in 6% (10,034 of 164,996) of hospitalizations with an ICU admission.
Antipsychotics were administered to 11% (17,764 of 164,996) of patients. Of the antipsychotics studied, the most
frequently used were haloperidol (62%; n = 10,958) and quetiapine (31%; n = 5,448). Delirium was associated with
increased ICU LOS (5 vs. 3 days, P < 0.001) and hospital LOS (11 vs. 6 days, P < 0.001), but not in-hospital mortality
(8% vs. 9%, P = 0.419). Antipsychotic exposure was associated with increased ICU LOS (8 vs. 3 days, P < 0.001),
hospital LOS (14 vs. 5 days, P < 0.001) and mortality (12% vs. 8%, P < 0.001). Of patients with antipsychotic
exposure in the ICU, absence of a documented mental disorder (32%, n = 5,760) was associated with increased ICU
LOS (9 vs. 7 days, P < 0.001), hospital LOS (16 vs. 13 days, P < 0.001) and in-hospital mortality (19% vs. 9%, P <
0.001) compared to patients with a documented mental disorder (68%, n = 12,004).
Conclusions: The incidence of documented delirium in ICU patients is lower than that documented in previous
prospective studies with active screening. Antipsychotics are administered to 1 in every 10 ICU patients. When
administration occurs in the absence of a documented mental disorder, antipsychotic use is associated with an
even higher ICU and hospital LOS, as well as in-hospital mortality.
Introduction
Delirium is an acute cognitive impairment defined by
fluctuating mental status, inattention and disorganized
thought. Intensive care unit (ICU) delirium is an inde-
pendent risk factor for increased mortality, time on
mechanical ventilation, ICU length of stay (LOS) and
hospital LOS [1-4]. The Society of Critical Care Medi-
cine recommends routine assessment in the ICU for the
presence of delirium [5]. Despite the significant
morbidity associated with delirium and this call for
proactive screening, documentation of the disorder is
highly variable. A recent survey of critical care health
professionals found that 86% believe that delirium is
underdiagnosed, 41% still do not screen for the disease
and only 20% use a validated delirium-screening tool [6].
Several antipsychotics (haloperidol, olanzapine, quetia-
pine, risperidone and ziprasidone) have been studied for
the treatment of ICU delirium [7-10]. Evidence-based
guidelines for appropriate medical management of delir-
ium are scant and a high variability of prescribing pat-
terns has been observed [6]. Within our own institution,
we have noted that some clinicians utilize the sedating
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properties of atypical antipsychotics in ICU patients to
alleviate insomnia or treat acute agitation, but these
patients may not have the diagnosis of delirium or a
mental disorder. In other cases, some patients will be
initiated on an antipsychotic in the ICU with little-to-no
documentation regarding the indication for therapy.
Because of these observations, we suspect that antipsy-
chotics are currently used in the ICU when a clear indi-
cation for therapy is not specified. Delirium appears to
be underappreciated and treated inappropriately with
benzodiazepines or narcotics, which may exacerbate the
delirious state in a dose-dependent relationship [1-3].
Prospective trials reveal the incidence of ICU delirium
to be as high as 60% [3], with an even higher prevalence
in the mechanically ventilated patient [1,2,11-14]. Data
from our single institution with no active delirium
screening found that International Classification of Dis-
eases, ninth revision (ICD-9) codes for delirium were
only documented in 2% of patients with an ICU admis-
sion and antipsychotics were administered to 9.8% of
patients in the ICU [15]. Curiously, 43% of patients who
were administered antipsychotics did not have an ICD-9
diagnosis code for a mental disorder or delirium. Based
on these data, we suspect that in clinical practice the
appreciation for and appropriate diagnosis of delirium
are actually much lower than the incidence reported in
trials with active delirium screening. Using a national
database, we hypothesized that the incidence of docu-
mented delirium is low and that antipsychotic adminis-
tration in the ICU occurs independently of a
documented mental disorder (including delirium).
Materials and methods
Data source
We performed a retrospective cohort study using diag-
nosis and medication administration data submitted to
the Clinical Database/Resource Manager (CDB/RM) at
the University HealthSystem Consortium (UHC) [16].
The UHC is an alliance of 113 academic medical centers
and 256 affiliated hospitals, which represent approxi-
mately 90% of the nation’s non-profit academic medical
centers. Consortium members enrolled in the database
submit hospital encounter information upon patient
discharge.
Among the information contained in the database are
patient demographics, diagnosis and procedure codes,
LOS, in-hospital mortality, ICU day resource utilization
and medication administration in the ICU. The CDB/
RM includes patient severity of illness and risk of mor-
tality scores generated from 3M™ All Patient Refined
Diagnosis Related Groups software (3M Health Informa-
tion Systems, Salt Lake City, UT, USA) which uses ICD-
9 diagnosis and procedure codes to classify patients into
four categories each for severity of illness and risk of
mortality: mild, moderate, major and extreme. Both
admission and discharge scores are tabulated – the for-
mer by excluding all diagnosis codes that were not pre-
sent on admission, and the latter using all diagnosis
codes submitted. UHC also generates flags for chronic/
comorbid conditions based on definitions adopted by
the Agency for Healthcare Research and Quality. The 29
comorbidities are correlated with resource utilization
and severity of illness [17].
The UHC has created Medicare Severity Diagnosis
Related Group level risk-adjustment models for three
outcomes of care: cost, LOS and hospital mortality.
When appropriate, the models incorporate admission
severity of illness and risk of mortality, Agency for
Healthcare Research and Quality chronic/comorbid con-
ditions, age, gender, race, socioeconomic status (use
payer source as a surrogate), admission status, admission
source, and diagnoses and procedures pertinent to mod-
eled patient populations. In-hospital mortality and LOS
expected values are calculated for every discharge and
can then be aggregated for various patient cohorts. The
UHC CDB/RM reporting system generates aggregate
results, and not patient specific output.
Patient population
This study was approved by the Institutional Review
Board of The Methodist Hospital Research Institute and
was granted a waiver of informed consent. We included
patient data submitted by all UHC-enrolled hospitals
participating in the Clinical Resource Manager database
(71 academic medical centers) with pharmacy clinical
resources for all patients 18 years of age or older who
were admitted from 1 January 2010 through 30 June
2010 with at least one day of ICU care. We used ICD-9
diagnosis codes to identify patients with delirium. Delir-
ium was defined as the following ICD-9 diagnosis codes:
290.11, 290.3, 290.41, 291.0 to 291.9, 292.81, 293.0 to
293.1, 293.9, 300.11, 308.09, 780.02, and 780.09. Mental
disorders, which include delirium, were defined as the
following ICD-9 diagnosis codes: 290 to 319, 780.02,
and 780.09. Exposure to antipsychotics was defined as
medication utilization in the ICU and included the fol-
lowing medications: aripiprazole, clozapine, haloperidol
oral, haloperidol decanoate injection, haloperidol lactate
injection, olanzapine, paliperidone oral, paliperidone pal-
mitate injection, quetiapine, risperidone and ziprasidone.
Data elements
We reviewed patient characteristics (gender, race, sex,
age over 65 years and admission severity of illness),
diagnoses of mental disorders and delirium, antipsycho-
tic exposure, and clinical outcomes (ICU LOS, hospital
LOS, expected hospital LOS, in-hospital mortality and
expected in-hospital mortality). Patient cohorts were
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compared based on documentation of delirium and anti-
psychotic exposure. A subgroup analysis of patients with
antipsychotic exposure was performed comparing
patients with a documented mental disorder versus
those without.
Statistical analysis
Descriptive statistics were generated from CDB/RM and
displayed as percentages for nominal data and median
accompanied by interquartile range (IQR) for continu-
ous variables that were not normally distributed. Infer-
ential statistics compared baseline characteristics,
clinical outcomes and antipsychotic exposure between
cohorts using chi-square tables and Fisher’s exact tests
for categorical variables and Mann-Whitney U tests for
ordinal data and continuous variables that were not nor-
mally distributed. Odds ratio was calculated using binary
logistic regression of two-by-two contingency tables.
Data were tested for normality using the Anderson-Dar-
ling Normality Test with a P-value < 0.05 signifying




Between 1 January 2010 and 30 June 2010, there were
164,996 hospitalizations with at least one day of ICU
stay. Fifty-six percent of patients were male, 64% were
Caucasian, and 54% were admitted to a surgical ICU.
Demographics for patients with regard to documentation
of delirium and exposure to antipsychotics are summar-
ized in Table 1. Documentation of delirium was present
in only 6% (n = 10,034) of hospitalizations with an ICU
admission. The incidence of documentation of delirium
among individual hospitals was low (6%, IQR 4.3% to
7.7%), with no hospital reporting an incidence above 20%
(Figure 1). The majority of delirium was documented as
delirium due to a general medical condition (34%, n =
3,433; ICD-9 codes 293.0 to 293.1), alcohol withdrawal
delirium (31%, n = 3,060; ICD-9 codes 291 to 291.9), and
delirium not otherwise specified (27%, n = 2,698; ICD-9
code 780.09). Documentation of a mental disorder,
including delirium, was present in 43% (n = 70,206) of
hospitalizations with an ICU admission.
Exposure to antipsychotics in the ICU occurred in 11%
(n = 17,764) of hospitalizations with an ICU admission.
The incidence of antipsychotic exposure among indivi-
dual hospitals was variable (10%, IQR 7.8% to 13.2%)
(Figure 1). Of the antipsychotics studied, the most fre-
quently used was haloperidol (62%; n = 10,958) followed
by quetiapine (31%; n = 5,448), risperidone (15%; n =
2,692), olanzapine (13%; n = 2,262), ziprasidone (4%; n =
684), aripiprazole (3%; n = 584), clozapine (0.4%; n = 71),
and paliperidone (0.2%; n = 40) (Figure 2). Patients with
documentation of delirium were more likely to receive an
antipsychotic versus patients without documentation of
delirium (39% vs. 9%, P < 0.001) (Table 2). This study
included three atypical antipsychotics (aripiprazole, clo-
zapine and paliperidone) that have not been studied for
the treatment of delirium. These three agents were rarely
used (0.4%, 695 of 164,996), given predominately to
patients with a documented mental disorder (84%, 583 of
695), and given infrequently to patients with documented
delirium (12%, 86 of 695). Only 68% (12,004 of 17,764) of
patients with antipsychotic exposure had documentation
of a mental disorder (Table 3).
Clinical outcomes
For all hospitalizations with an ICU admission, the med-
ian ICU LOS was three days (IQR 2 to 5), median hos-
pital LOS was six days (IQR 3 to 12), and in-hospital
mortality was 9%. Patients with documentation of delir-
ium versus patients without documentation of delirium
had an increased ICU LOS (5 vs. 3 days, P < 0.001) and
hospital LOS (11 vs. 6 days, P < 0.001), but not in-hos-
pital mortality (8% vs. 9%, P = 0.419). Based on UHC
CDB/RM hospital LOS and mortality model predictions,
patients with delirium stayed in the hospital longer than
expected (11 observed days vs. 10 expected days, P <
0.001) but die in-hospital less often than expected (8%
observed mortality vs. 12% expected mortality, P <
0.001). Outcomes for patients with regard to documen-
ted delirium are summarized in Table 4.
Patients exposed to antipsychotics in the ICU versus
patients without antipsychotic exposure had an
increased ICU LOS (8 vs. 3 days, P < 0.001), hospital
LOS (14 vs. 5 days, P < 0.001), and in-hospital mortality
(12% vs. 8%, P < 0.001). Based on UHC CDB/RM hospi-
tal LOS and mortality model predictions, patients with
antipsychotic exposure stayed in the hospital longer
than expected (14 observed days vs. 13 expected days, P
< 0.001) but die in-hospital less often than expected
(12% observed mortality vs. 14% expected mortality, P <
0.001). Outcomes for patients with regard to antipsycho-
tic exposure are summarized in Table 4.
Subgroup analysis of patients with antipsychotic expo-
sure found patients without a documented mental disor-
der diagnosis, as compared to patients with a mental
disorder, had an increased ICU LOS (9 vs. 7 days, P <
0.001), hospital LOS (16 vs. 13 days, P < 0.001), and in-
hospital mortality (19% vs. 9%, P < 0.001) (Table 5).
Based on UHC CDB/RM hospital LOS and mortality
prediction models, patients exposed to antipsychotics
without a documented mental disorder stayed in the
hospital longer than expected (16 observed days vs. 14
expected days; P < 0.001) and died in-hospital more
often than expected (19% observed mortality vs. 16%
expected mortality; P < 0.001).
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Discussion
Despite the fact that prospective clinical trials with
active screening for delirium have shown that delirium
occurs in 20% to 60% of critically ill patients
[1-3,11-14], this retrospective review of 71 academic
medical centers in the United States found that this dis-
ease is only documented in 6% of critically ill patients.
Therefore, a majority of delirium is either undiagnosed
or the diagnosis of delirium is not being documented
using ICD-9 diagnosis codes. Contemporary clinical
trials demonstrate that delirium is an independent risk
factor of mortality and other unfavorable outcomes
[1-4], and the absence of recognition of delirium using
ICD-9 diagnosis codes represents an opportunity for
improvement for the critical care medicine community.
The low incidence of documented delirium has led the
authors to hypothesize that most hospitals (similar to
our institution) were not actively screening for delirium
[6] as recommended in the 2002 Society of Critical Care
Medicine guidelines [5]. In the absence of active screen-
ing, it is likely that only cases of the highly-visible
hyperactive type of delirium (a minority subset of delir-
ium) were diagnosed and documented with ICD-9 diag-
nosis codes and the less-visible hypoactive type of
delirium (the majority of delirium) was missed [1]. Even
though physicians and nurses may feel confident in
their ability to diagnose delirium, using clinical judg-
ment for diagnosis of delirium misses 70% of delirium
compared to a standardized screening tool such as the
Confusion Assessment Method for the ICU (CAM-ICU)
[18]. The CAM-ICU is a validated delirium screening
tool that takes an average of two minutes to conduct
and can be implemented with minimal training [11,13].
Institutions that are interested in adopting the CAM-
























Age ≥65 years, n (%) 59,550 3,937 55,613 < 6,444 50,383 0.181
(36.1) (39.3) (35.7) 0.001 (36.3) (35.8)
Male sex, n (%) 92,157 6,499 85,658 < 10,884 77,686 <
0.001
(55.9) (64.8) (55.3) 0.001 (61.3) (55.2)
Surgical ICU type, n (%) 89,423 4,850 84,573 < 9,930 76,693 <
0.001
(54.2) (48.3) (54.6) 0.001 (55.9) (54.4)
Race
White, n (%) 105,565 7,072 98,493 < 12,272 89,055 <
0.001
(64.0) (70.5) (63.6) 0.001 (69.1) (63.2)
Black, n (%) 34,647 1,647 33,000 < 3,173 30,061 <
0.001
(21.0) (16.4) (21.3) 0.001 (17.9) (21.3)
Other, n (%) 24,784 1,315 23,469 < 2,319 21,749 <
0.001
(15.0) (13.1) (15.1) 0.001 (13.1) (15.4)
Admit severity of illness
Minor, n (%) 23,619 526 23,093 < 993 18,007 <
0.001
(14.3) (5.2) (14.9) 0.001 (5.6) (14.7)
Moderate, n (%) 47,543 2,064 45,479 < 3,150 35,956 <
0.001
(28.8) (20.6) (29.3) 0.001 (17.7) (29.4)
Major, n (%) 57,747 4,067 53,680 < 6,386 42,471 0.002
(35.0) (40.5) (34.6) 0.001 (36.0) (34.7)
Extreme, n (%) 36,083 3,377 32,706 < 7,234 25,830 <
0.001
(21.9) (33.7) (21.1) 0.001 (40.7) (21.1)
Results compare patients with an admission to an intensive care unit with documentation of delirium versus none and with antipsychotic exposure versus none
(n = 164,996). aDue to equivocal data for antipsychotic administration, 4% (n = 6,337) of patients were excluded from antipsychotic exposure versus no
antipsychotic exposure comparisons. It is likely that these patients received an antipsychotic while hospitalized, but administration while in the ICU could not be
confirmed. ICU, intensive care unit
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Figure 1 Box plot showing incidence of documented delirium and antipsychotic exposure by hospital. Results report data in aggregate
by hospital for 71 Hospitals in the United States (n = 164,996). Medians labeled; Boxes, 25th, 50th (median), and 75th percentiles; bars, maximum
and minimum values that were not outliers; asterisk, outliers; One extreme outlier (67%) for ICU Antipsychotic Exposure is not shown.
Figure 2 Individual antipsychotic frequency of use. Results show data for patients with an admission to an intensive care unit with and
without documentation of a mental disorder (n = 164,996). Data are not shown for antipsychotics which were used in less than 1% of
admissions: clozapine (0.4%) and paliperidone (0.2%).
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ICU screening tool can obtain free access to training
manuals, reference material and training videos online
at the ICU Delirium and Cognitive Impairment Study
Group website [19].
This study found that the documentation of delirium
is associated with a significant increase in ICU and hos-
pital LOS, but not mortality. The clinician should use
caution when interpreting this outcome data, as the 6%
incidence of documented delirium was much less than
the incidence of 20% to 60% [1-3,11-14] in studies with
prospectively collected data with routine delirium-
screening assessments. Expectedly, patients with docu-
mented delirium had a higher severity of illness at
admission, which is likely to increase LOS. Severity of
illness is a variable used to generate the UHC expected
LOS. In this study, the observed LOS was longer than
the expected LOS for patients with documented delir-
ium. This study is unable to determine if delirium
causes an increase in the ICU LOS and hospital LOS or
if patients with increased ICU LOS and hospital LOS
are more likely to be diagnosed or receive documenta-
tion of a diagnosis. Patients with documented delirium
had similar in-hospital mortality compared to patients
without documented delirium, even though several pro-
spective observational studies have correlated delirium
with a significant increase in in-hospital mortality [2,4].
Also, the incidence of observed mortality was less than
the UHC-expected mortality for these patients with
documented delirium. The authors hypothesize that
delirium was not associated with mortality in this study
because only a small subset (most likely the hyperactive
type) of truly delirious patients received a documenta-
tion of delirium using ICD-9 diagnosis codes.
Antipsychotics were administered in the ICU to 11%
of hospitalizations with an ICU admission. Haloperidol
was the most frequently used antipsychotic, which is
consistent with the 2002 Society of Critical Care Medi-
cine guidelines [5] and a recent survey [6] in which 86%
of health professionals reported using haloperidol to
treat delirium compared to 40% who reported using aty-
pical antipsychotics. This study found that patients with
documented delirium were six times more likely to
receive an antipsychotic. Since the publication of the
2002 Society of Critical Care Medicine guidelines, trials
have studied four atypical antipsychotics (quetiapine,
olanzapine, risperidone and ziprasidone) for the treat-
ment of ICU delirium [7-10]. These trials have consisted
of very small sample sizes and must be interpreted with
caution. Of these four atypical antipsychotics, these
results found quetiapine to be used most often in ICU
patients. Ziprasidone was used least often, which may
reflect hesitation to use this medication since it carries a
black box warning for QTc prolongation. Exposure to
antipsychotics was associated with increased ICU LOS,
hospital LOS and in-hospital mortality. However, the
observed mortality was less than the expected mortality












Antipsychotic exposure 3,883 13,880 6.4 (6.1 to 6.7) < 0.001
(38.7) (9.0)
Haloperidol 3,014 7,969 7.9 (7.6 to 8.3) < 0.001
(30.0) (5.1)
Quetiapine 1,271 4,189 5.2 (4.9 to 5.6) < 0.001
(12.7) (2.7)
Risperidone 497 2,199 5.8 (5.2 to 6.3) < 0.001
(5.0) (1.4)
Olanzapine 592 1,676 3.6 (3.3 to 4.0) < 0.001
(5.9) (1.1)
Ziprasidone 140 545 4.0 (3.3 to 4.8) < 0.001
(1.4) (0.4)
Aripiprazole 75 509 2.3 (1.8 to 2.9) < 0.001
(0.7) (0.3)
Clozapine 10 61 2.5 (1.3 to 5.0) < 0.001
(0.1) (0.0)
Paliperidone 1 39 0.4 (0.1 to 2.9) 0.516
(0.0) (0.0)
Results show data for patients with an admission to an intensive care unit with and without documentation of a mental disorder (n = 164,996). CI, confidence
interval
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for these patients. It is unknown if exposure to antipsy-
chotics caused increased ICU LOS and hospital LOS, or
if patients with longer hospitalizations were more likely
to be exposed to an antipsychotic because they stayed
longer. The correlation between antipsychotics and out-
comes in this retrospective study may be heavily influ-
enced by selection bias, and patients who were
refractory to other interventions may have been more
likely to receive antipsychotic therapy. Large prospective
randomized trials are needed to determine if there is a
cause-and-effect relationship between antipsychotic
exposure in the ICU and ICU LOS, hospital LOS and
in-hospital mortality.
A subgroup analysis of patients who were exposed to
antipsychotics was conducted to elicit any potential dif-
ferences in patient demographics and clinical outcomes
for patients regarding documentation of a mental disor-
der (which served as a surrogate marker for indication
of therapy). Of patients exposed to antipsychotics, 32%
did not have documentation of a mental disorder.
Table 3 Basic demographics and clinical characteristics of patients with antipsychotic exposure
Demographics and clinical
characteristics










Age ≥65 years, n (%) 3,807 2,637 < 0.001
(31.7) (45.8)
Male sex, n (%) 7,293 3,591 0.042
(60.8) (62.4)
Surgical ICU type, n (%) 6.177 3.753 < 0.001
(51.5) (65.2)
Race
White, n (%) 8,359 3,913 0.021
(69.6) (67.9)
Black, n (%) 2,192 981 0.045
(18.3) (17.0)
Other, n (%) 1,453 866 < 0.001
(12.1) (15.0)
Admit severity of illness
Minor, n (%) 694 299 0.109
(5.8) (5.2)
Moderate, n (%) 2,287 864 < 0.001
(19.1) (15.0)
Major, n (%) 4,434 1,951 < 0.001
(36.9) (33.9)
Extreme, n (%) 4,588 2,646 < 0.001
(38.2) (45.9)
Results show data for patients with an admission to an ICU with administration of an antipsychotic while in the ICU (n = 17,764). Table compares data for
patients with and without documentation of a mental disorder. ICU, intensive care unit












ICU LOS, median days (IQR) 5 (3 to 10) 3 (2 to 5) < 0.001 8 (4 to 15) 3 (2 to 4) < 0.001
Hospital LOS
Observed, median days (IQR) 11 (6 to 19) 6 (3 to 11) < 0.001 14 (7 to 24) 5 (3 to 10) < 0.001
Expected, median days (IQR) 10 (7 to 15) 7 (5 to 10) < 0.001 13 (9 to 21) 7 (5 to 10) < 0.001
Mortality
Observed, % 8.3 8.6 0.419 12.2 8.1 < 0.001
Expected, % 11.5 8.3 < 0.001 14.0 7.8 < 0.001
Results compare outcomes for patients with an admission to an intensive care unit with documentation of delirium versus none and with antipsychotic exposure
versus none (n = 164,996). aDue to equivocal data for antipsychotic administration, 4% (n = 6,367) of patients were excluded from antipsychotic exposure versus
no antipsychotic exposure comparisons. ICU, intensive care unit; LOS, length of stay
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Patients exposed to antipsychotics without documenta-
tion of a mental disorder were also more likely to be
elderly and have an extreme admission severity of ill-
ness, which is concerning, as atypical antipsychotics
carry a black box warning for increased mortality in
elderly patients. Clinical outcomes were different
between groups as patients without documentation of a
mental disorder had increased ICU LOS, hospital LOS
and over twice the mortality compared to patients with
documentation of a mental disorder. This study found
that neither the documentation of delirium nor the
exposure to antipsychotic medication in the ICU alone
were associated with an in-hospital mortality that was
higher than expected. However, observed morality was
higher than expected for patients who received antipsy-
chotics when there was no documentation of a mental
disorder (including delirium).
Several limitations must be considered when interpret-
ing this study. This observational study found an unu-
sually low incidence of documented delirium that is
mostly likely attributable to low rates of documentation
of diagnosed delirium or a low incidence of delirium
diagnosis due to improper screening. This study utilized
ICD-9 diagnosis codes that are collected for billing pur-
poses and not for research. The low incidence of docu-
mented delirium found in this trial should not be
misconstrued to indicate a low rate of disease occur-
rence, since the methods used to screen for delirium at
these hospitals is unknown. Low rates of documentation
could be explained by variable nomenclature (that is,
acute encephalopathy, ICU psychosis, toxic psychosis,
and so on) that may result in inaccurate ICD-9 diagno-
sis coding. The authors tried to account for this by
using 11 ICD-9 codes for delirium. The authors are
unable to estimate how many patients were diagnosed
with delirium, yet never received documentation of this
diagnosis using one of these 11 ICD-9 codes. The UHC
database allows up to 99 ICD-9 codes per admission,
and it is unlikely that ICD-9 codes reported from the
hospital were truncated in the UHC database. One
hypothesized limitation was that ICD-9 codes were only
being collected for reimbursement (MS-DRG accounts
for the first nine ICD-9 codes). Further review of the
UHC database found that at least 40% of patients had
more than nine ICD-9 codes and 50% of the ICD-9
codes for delirium occurred after the ninth position.
Based on this information, the authors believe that the
potential impact of hospitals reporting ICD-9 codes to
UHC that are only associated with financial incentive is
minimal. This study is unable to determine what diag-
nostic tool, if any, was used for the diagnosis of delir-
ium. This UHC CDB/RM electronic data are reported in
groups by hospital or in aggregate; therefore, we were
unable to perform multivariate analysis to correlate
delirium or antipsychotic exposure as an independent
risk factor for clinical outcomes. Patient variables, such
as biomarkers of organ function, were not available in
this database. Therefore, this study was unable to com-
pare patient groups using traditional baseline severity of
illness scoring systems. However, UHC has provided
admission severity of illness, expected hospital LOS and
expected mortality for patients using reggression-model-
ing and independent risk factors. We have compared
observed data to these expected values where applicable.
Diagnosis codes are recorded for each hospitalization
and are not specific for diagnosis during ICU days. This
study did not capture the incidence of ICD-9 codes that
were present-on-admission versus new diagnoses.
There were equivocal data regarding antipsychotic
medication use for 4% (n = 6,367) of patients. It is likely
that these patients received an antipsychotic while hos-
pitalized, but administration while in the ICU could not
be confirmed. Therefore, these patients were excluded
from antipsychotic exposure versus no antipsychotic
exposure comparisons. We were not able to quantify the
dose or number of doses of antipsychotic administered
to patients, and data were analyzed dichotomously as
“exposed” or “not exposed.” While several formulations
of haloperidol were available as options in the database,
a sub analysis of intravenous versus oral haloperidol was
Table 5 Clinical outcomes of patients with antipsychotic exposure
Clinical outcomes Antipsychotic exposure and mental disorder
12,004
(68%)




ICU LOS, median days (IQR) 7 (4 to 14) 9 (4 to 18) < 0.001
Hospital LOS
Observed, median days (IQR) 13 (7 to 23) 16 (8 to 28) < 0.001
Expected, median days (IQR) 12 (9 to 20) 14 (9 to 22) < 0.001
Mortality
Observed, % 9.0 18.7 < 0.001
Expected, % 12.8 16.4 < 0.001
Results show data for patients with an admission to an ICU with administration of an antipsychotic while in the ICU (n = 17,764). Table compares data for
patients with and without documentation of a mental disorder. ICU, intensive care unit. ICU, intensive care unit; IQR, interquartile range; LOS, length of stay.
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not conducted since many hospitals did not specify the
formulation that was used. Regarding the subgroup ana-
lysis of patients receiving antipsychotics, this study is
unable to determine the clinician’s intended indication
for antipsychotic therapy. All approved indications for
antipsychotic therapy were accounted for in the group
of ICD-9 diagnosis codes used to define a mental
disorder.
Conclusions
This report demonstrates that the incidence of docu-
mented delirium in ICU patients is lower than that
documented in previous prospective studies. We
hypothesize that the low rates of documented delirium
using ICD-9 diagnostic codes is attributable to improper
screening of delirium, which was the case at our institu-
tion. This study suggests that hospitals are not routinely
assessing for delirium as recommended by the Society of
Critical Care Medicine and that a national culture
change is needed to increase the awareness and diagno-
sis of delirium.
Antipsychotics are administered to 1 in every 10 ICU
patients, and exposure to these medications is associated
with increased ICU and hospital LOS. Patients exposed
to an antipsychotic, when there is no documentation of
a mental disorder, have increased ICU LOS, hospital
LOS and mortality compared to patients with documen-
tation of a mental disorder. These findings do not sup-
port the use of antipsychotic medications in the ICU
when patients do not have a documented diagnosis of a
mental disorder or delirium. The appropriate indication
and agent selection of the antipsychotics should con-
tinue to be studied in prospective, randomized, con-
trolled trials. Due to the high prevalence of
antipsychotic use in ICU patients who do not have a
documented mental disorder, future studies are needed
to describe the specific indications for antipsychotics
and common doses that are being used in critically ill
patients in current clinical practice.
Key messages
• The incidence of documented delirium in a nation-
wide cohort was only 6% in patients who had at least
one day of ICU care, which is likely attributable to
poor rates of screening, diagnosis and
documentation.
• Antipsychotic medications were administered in
the ICU to 11% of patients.
• Patients with documented delirium were six times
more likely to receive antipsychotics in the ICU.
• The most frequently used antipsychotic was
haloperidol.
• Patients exposed to antipsychotic medications
when there is no documented diagnosis of a mental
disorder (including delirium) had worse clinical
outcomes.
• These findings do not support the use of antipsy-
chotic medications in the ICU when patients do not
have a documented diagnosis of a mental disorder
or delirium.
Abbreviations
CDB/RM: Clinical Database/Resource Manager; CI: confidence interval; ICD-9:
International Classification of Diseases: ninth revision; ICU: intensive care unit;
IQR: interquartile range; LOS: length of stay; UHC: University HealthSystem
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